Melane Sampson, Author at BioTuesdays

Developments

EC and Swissmedic approve KalVista’s oral treatment for HAE

KalVista Pharmaceuticals (NASDAQ: KALV) announced that the European Commission (EC) and Swiss Agency for Therapeutic Products (Swissmedic) have approved EKTERLY (sebetralstat), a novel, oral plasma kallikrein inhibitor...

September 19, 2025

Developments

Palisade announces positive PALI-2108 data

Palisade Bio (NASDAQ: PALI) has announced new data from its ongoing clinical program evaluating PALI-2108, a first-in-class, ileocolonic-targeted PDE4 B/D inhibitor. The company plans to present the results in an oral...

September 17, 2025

Developments

Vivos unveils landmark trial results in pediatric OSA treatment

Vivos Therapeutics (NASDAQ: VVOS) has announced first time, peer-reviewed published data confirming that the Vivos Daytime-Nighttime Appliance (DNA) is both safe and efficacious in treating children suffering from...

September 17, 2025

Developments

Adagene, Exelixis amend license agreement to develop third masked mAb

Adagene (NASDAQ: ADAG) has announced an amendment to the 2021 collaboration and license agreement with Exelixis (Nasdaq: EXEL) to enable the development of a third novel masked monoclonal antibody (mAb) drug conjugate...

September 16, 2025

Executive Moves

Lucid appoints policy leader Danielle Scelfo as SVP, Market Access & Gov’t Affairs

Lucid Diagnostics (NASDAQ: LUCD) announced the appointment of Danielle Scelfo as SVP, Market Access & Government Affairs, reporting to the CEO. With more than 25 years of strategic and operational experience across...

September 16, 2025

Developments

Actinogen, FDA agree on activities toward marketing approval of Xanamem for AD

Actinogen Medical (ASX: ACW) has announced that an agreement with the FDA has been reached in a scheduled Type C meeting on the manufacturing, clinical, and nonclinical activities required for a future US marketing...

September 16, 2025

Developments

Entera reports positive data for oral GLP-2 tablet for SBS at 2025 ESPEN Congress

Entera Bio (NASDAQ: ENTX) has announced the presentation of a poster highlighting pharmacokinetic data relating to its first-in-class oral GLP-2 analog program for the treatment of short bowel syndrome (SBS), at the...

September 16, 2025

Feature

Exousia Pro progressing scalable DNA-loaded exosomes toward the clinic

Exousia Pro (OTCPINK: MAJI) is developing a next-generation drug delivery platform using plant-based exosomes and a proprietary manufacturing process that could potentially address the biggest challenges in the...

September 16, 2025

Executive Moves

ALX appoints Dr. Barbara Klencke as interim CMO

ALX Oncology Holdings (NASDAQ: ALXO) has announced the appointment of board member Barbara Klencke, MD, as interim chief medical officer, (CMO). According to ALX, Dr. Alan Sandler is departing from the role of CMO and...

September 12, 2025

Developments

Cocrystal showcases potential first oral antiviral for norovirus

Cocrystal Pharma (NASDAQ: COCP) has announced that the scientific foundation and clinical progress of its lead pan-viral protease inhibitor, CDI-988, was discussed by President and CEO, Dr. Sam Lee, in a presentation at...

September 12, 2025

Author - Melane Sampson

EC and Swissmedic approve KalVista’s oral treatment for HAE

Palisade announces positive PALI-2108 data

Vivos unveils landmark trial results in pediatric OSA treatment

Adagene, Exelixis amend license agreement to develop third masked mAb

Lucid appoints policy leader Danielle Scelfo as SVP, Market Access & Gov’t Affairs

Actinogen, FDA agree on activities toward marketing approval of Xanamem for AD

Entera reports positive data for oral GLP-2 tablet for SBS at 2025 ESPEN Congress

Exousia Pro progressing scalable DNA-loaded exosomes toward the clinic

ALX appoints Dr. Barbara Klencke as interim CMO

Cocrystal showcases potential first oral antiviral for norovirus

Subscribe